Lonza publishes restated 2025 figures, shares react to CHI divestment ahead half-year release
23.06.2026 - 13:02:44 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:01.
Lonza Group AG (CH0013841017) has published restated Half-Year 2025 financial information that reclassifies its Capsules & Health Ingredients business as discontinued operations, ahead of its Half-Year 2026 results due in July, according to an ad hoc statement on SIX Swiss Exchange.
What the ad hoc release says
In a release dated 23 June 2026, Lonza states that the restated Half-Year 2025 numbers reflect the CHI business as discontinued operations, aligned with the Full-Year 2025 reporting format already used for the segment. IR release of 23 June 2026 The company highlights that the restatement covers the consolidated income statement and selected key performance measures for the 2025 half-year period, but does not alter previously reported Full-Year 2025 results.
The move follows Lonza’s December 2024 decision to divest CHI and its subsequent agreement on 6 March 2026 to sell the business to Lone Star Funds, with closing expected in the third quarter of 2026. Marketscreener summary of the transaction The ad hoc communication is made under Article 53 of the SIX Swiss Exchange Listing Rules, underlining the regulatory relevance of the reclassification for investors in Switzerland.
Consensus and upcoming earnings focus
Lonza’s restated Half-Year 2025 figures come less than a month before the scheduled release of Half-Year 2026 results on 22 July 2026, a date flagged in the company’s investor relations calendar. Lonza earnings calendar On MarketScreener, Lonza is tracked as a biotechnology group with ticker LONN on SIX, where the latest real-time indicative price around midday on 23 June 2026 shows 508.60 Swiss francs, down about 2.4 percent over five days. MarketScreener price and consensus overview
Consensus data compiled on such platforms indicate that Lonza is typically covered by a range of European houses like UBS and Deutsche Bank alongside international banks, with a mix of Buy and Hold recommendations and a focus on margins and growth in biologics manufacturing. While individual price targets vary, analysts generally treat the CHI sale as a portfolio simplification that should sharpen Lonza’s exposure to higher-margin contract development and manufacturing services.
All news and analysis on the Lonza Group AG shares
Further background, historical reports and intraday price data on the Lonza stock are available in the dedicated topic section and directly from the company’s investor relations pages.
The business behind the CHI divestment
Lonza’s Capsules & Health Ingredients unit, now classified as discontinued operations in the restated Half-Year 2025 accounts, manufactures hard gelatin and vegetarian capsules, as well as nutritional ingredients used by pharmaceutical and nutraceutical customers. The divestment to Lone Star Funds is part of Lonza’s strategy to focus on its core contract development and manufacturing organization activities, where it provides biologics, small molecule and cell and gene therapy manufacturing services to global pharma and biotech clients.
Where the Lonza shares trade today
Lonza Group AG shares (CH0013841017) trade on 2026-06-23, 10:56 on SIX Swiss Exchange at an indicative 508.60 Swiss francs, based on MarketScreener’s real-time estimate. The stock’s market reference is therefore the Swiss franc quotation in Zurich, where Lonza is part of the Swiss large-cap universe.
Key data on the Lonza shares
- Company: Lonza Group AG
- ISIN: CH0013841017
- WKN: 928619
- Ticker: LONN
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-23, 10:56): 508.60 CHF
- Market cap: approximately 38 billion CHF (as of 2026-06-23)
- Sector / industry: Biotechnology / Life Sciences Tools & Services
- Index membership: SMI / SPI
- Next earnings date: 2026-07-22
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on sources believed to be reliable but may be subject to change. Investors should conduct their own research or consult a professional advisor before making investment decisions.
